WARSAW, December 18, 2024 – Saventic Health, a Warsaw-based health-tech startup, has secured $2.1 million in bridge funding from 4growth VC, NCBR Investment Fund, and the U.S.-based TNI Fund. The funding aims to accelerate the company’s global expansion and advance its cutting-edge AI solutions for diagnosing rare diseases.
Since its inception in 2019, Saventic Health has developed a suite of 50 AI algorithms capable of identifying rare diseases, a healthcare challenge affecting 450 million people worldwide. Traditional diagnostic methods often take years to pinpoint rare conditions, but Saventic’s technology significantly shortens this timeline by analyzing electronic health records and providing actionable insights for physicians.
Global Reach and Expansion Plans
In the past year alone, Saventic Health’s algorithms have assisted in diagnosing over 200 rare disease cases. The company has a presence on three continents, collaborating with over 30 clinics and hospitals in Poland, Germany, France, and Brazil, and working with Canadian hospitals integrated through centralized electronic health records.
The latest funding will be channeled into expanding operations in Europe, with a focus on Austria, Sweden, Spain, and Italy, as well as deepening its footprint in South America. Projects are already underway in Brazil, and the company plans to enter markets in Colombia, Peru, and other digitally advanced countries in the region.
“Our international presence validates the effectiveness of our algorithms,” said Szymon Piątkowski, co-founder and CEO of Saventic Health. “The healthcare sector is transforming through AI, and our team’s expertise positions us as a key player in this space. Next year, we’ll focus on further geographic diversification and revenue growth, alongside preparing for a major Series A funding round.”
Strategic Investment Partnerships
The addition of the U.S.-based TNI Fund, part of Kluz Ventures, underscores Saventic’s potential as a transformative force in AI-driven healthcare. “Saventic Health represents the future of diagnostics,” said Artur Kluz, General Partner at TNI Fund. “Their innovative solutions address a critical need in global healthcare.”
4growth VC, a long-standing investor, increased its stake in this funding round. “The inclusion of a U.S. investor demonstrates Saventic’s global potential,” noted Tomasz Biłous, Managing Partner at 4growth VC. “Their digitalized processes enable rapid and scalable international growth.”
Ksenia Wójcik-Karasiewicz, CEO of NCBR Investment Fund, emphasized the importance of public-private partnerships in fostering innovation. “Saventic Health’s dynamic growth proves the value of combining public and private capital to support Polish companies on the global stage.”
A Growing Market Need
Rare diseases remain one of healthcare’s greatest challenges, with over 8,000 conditions identified but fewer than 10% well-understood. Traditional diagnostics rely on doctors’ expertise or costly trials, yielding low efficiency and long delays. Saventic Health’s AI-powered approach drastically improves efficiency and reduces costs, making it a game-changer in the field.
Founded by Piątkowski and Professor Grzegorz Basak, Saventic Health employs a team of nearly 40 specialists, including doctors and data scientists. With new funding and ambitious plans for expansion, the startup is poised to lead the transformation of rare disease diagnostics worldwide.
